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Cognitive impairment in Down syndrome (DS) has been linked to increased synaptic
inhibition. The underlying mechanisms remain unknown, but memory deficits are rescued
in DS mouse models by drugs targeting GABA receptors. Similarly, administration of
epigallocatechin gallate (EGCG)-containing extracts rescues cognitive phenotypes in
Ts65Dn mice, potentially through GABA pathway. Some developmental and cognitive
alterations have been traced to increased expression of the serine-threonine kinase
DYRK1A on Hsa21. To better understand excitation/inhibition balance in DS, we
investigated the consequences of long-term (1-month) treatment with EGCG-containing
extracts in adult mBACtgDyrk1a mice that overexpress Dyrk1a. Administration of
POL60 rescued components of GABAergic and glutamatergic pathways in cortex and
hippocampus but not cerebellum. An intermediate dose (60mg/kg) of decaffeinated
green tea extract (MGTE) acted on components of both GABAergic and glutamatergic
pathways and rescued behavioral deficits as demonstrated on the alternating paradigm,
but did not rescue protein level of GABA-synthesizing GAD67. These results indicate
that excessive synaptic inhibition in people with DS may be attributable, in large part,
to increased DYRK1A dosage. Thus, controlling the level of active DYRK1A is a clear
issue for DS therapy. This study also defines a panel of synaptic markers for further
characterization of DS treatments in murine models.
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Introduction
Down syndrome (DS), occurring in 1 in every 750 live births, encompasses a constellation of
features caused by partial or complete trisomy for chromosome 21 (Hsa21). In particular, an altered
copy number for segments of Hsa21 containing the dual-specificity tyrosine phosphorylated and
regulated kinase 1A (DYRK1a) gene can induce morphological defects and cognitive impairments
(Delabar et al., 1993; Ronan et al., 2007; van Bon et al., 2011). These defects have been
reproduced in a number of different mouse models of DS (Ts1Rhr, Ts65Dn, Ts1Cje, Dp(16)1Yey) as
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well as mice with altered copy numbers of Dyrk1a
(hBACtgDyrk1a, hYACtgDyrk1a, mBACtgDyrk1a, Dyrk1a+/−).
Interestingly, a phenotype rescue experiment crossing Ts65Dn
mice, which have three copies of Dyrk1a, with mice monosomic
for a 33-gene chromosomal segment containing Dyrk1a
(Ms1Rhr) produced progeny with a normal learning phenotype,
indicating that triplication of this 33-gene region is necessary
to produce the cognitive deficit (Belichenko et al., 2009). A
complete phenotypic assessment of Ts1Rhr mice, trisomic for the
33-gene segment, showed that trisomy of this region is sufficient
to produce significant alterations in behavioral tasks such as
the open-field, novel object recognition, and T-maze tasks. In
Ts65Dn, Ts1Cje, and Ts1Rhr mice, long-term potentiation (LTP)
in fascia dentata (FD) could be induced only after blocking
GABA(A)-dependent inhibitory neurotransmission. In addition,
widespread enlargement of dendritic spines and decreased
density of spines in FD were preserved (Haas et al., 2013). Thus,
cognitive impairment in DS appears to derive from molecular
and structural changes related to an altered copy number within
this 33-gene region.
Among the genes from this 33-gene region, Dyrk1a is
an attractive candidate for inducing cognitive impairment
phenotypes. DYRK1A, the mammalian ortholog of Drosophila
minibrain kinase (mnb) (Tejedor et al., 1995), encodes a
proline/arginine-directed serine/threonine kinase. Both in
trisomic mice and in individuals with DS, brain levels of
DYRK1A are increased approximately 1.5-fold, indicating
that this protein is overexpressed in a gene dosage-dependent
manner (Dowjat et al., 2007). Further, comparisons of mouse
models having different copy numbers of Dyrk1a have provided
important support for the hypothesized contribution of
DYRK1A to cognition. We previously assessed the molecular
(i.e., immunoblotting/immunohistochemistry) and behavioral
(e.g., rotarod, Morris water maze, Y-maze) consequences of
alterations in Dyrk1a dosage in mBACtgDyrk1a, Ts65Dn,
Dp(16)1Yey (each with 3 gene copies), and Dyrk1a+/− (one
functional copy) mice (Souchet et al., 2014). Increased expression
of DYRK1A in mBACtgDyrk1a induced molecular alterations
in synaptic plasticity pathways, particularly expression changes
in GABAergic- and glutaminergic-related proteins (Souchet
et al., 2014). Similar alterations were observed in models
with partial trisomy of Mmu16, Ts65Dn and Dp(16)1Yey,
and were reversed in the Dyrk1a+/− model. Further,
Dyrk1a overexpression produced an increased number (using
stereological methodology) and an increased signal intensity of
neurons expressing GAD67, an enzyme that synthesizes GABA,
indicating inhibition pathway alterations in three different
models. Functionally, DYRK1A overexpression protected mice
from PTZ-induced seizures related to GABAergic neuron
plasticity. DYRK1A dosage affects pathways involved in
synaptogenesis and synaptic plasticity and influences a shift in
E/I balance toward inhibition. Inhibition of DYRK1A activity
offers a therapeutic target for DS, but its inhibition/activation
may also be relevant for psychiatric disorders with E/I balance
alterations.
Many competitive inhibitors targeting the ATP binding site
of DYRK1A have been described; most also inhibit secondary
targets (Ogawa et al., 2010). A comparative analysis indicates
that epigallocatechin gallate (EGCG), a flavanol present in
green tea, appears to inhibit DYRK1A with PRAK, another
serine/threonine kinase, as a secondary target (Bain et al., 2003).
Interestingly, EGCG acts non-competitively at a site external to
the ATP binding site (Adayev et al., 2006).We previously assessed
the effect of lifelong EGCG treatment, beginning prenatally, on
the phenotype of the hYACtgDyrk1a mouse model. A dose of
50mg/kg resulted in normal memory as measured on the novel
object paradigm (Guedj et al., 2009). Following our report, a pilot
clinical study performed on a group of young adults with DS
found that a decaffeinated green tea extract (Mega Green Tea
Extract, MGTE) improved “episodic memory test” results of the
patients (De la Torre et al., 2014).
However, the mechanistic basis of the effects of EGCG
treatment is not clearly established at the molecular level.
Therefore, in the current study we investigated the molecular
effects of a commercial green tea extract, POL60, on murine
mBACtgDyrk1a and Ts65Dn models, at a dose similar to the one
used in our prior report. Specifically, we assessed the effects of
treatment on GABA (GAD67, GAD65, VGAT) and glutamate
(GLUR1, GLUR2, NR1, NR2A, VGLUT1) pathways and on
short-term memory. We also studied the effects of decaffeinated
MGTE, used in the pilot clinical trial, and compared them with
the effects of POL60 treatment as well as with a caffeine treatment
potentially interfering with the effect of EGCG. The findings of
these studies offer insights applicable to potential interventions to
improve E/I balance in people with DS as well as some psychiatric
disorders.
Materials and Methods
Experimental Mice
Mice were housed in standard cages with access to food and water
ad libitum, under a controlled environment (temperature =
20 ± 1◦C; humidity = 60%), and with a light/dark cycle of
12 h. All experiments were conducted in accordance with
the ethical standards of French and European regulations
(European Communities Council Directive, 86/609/EEC).
Official authorization from the French Ministry of Agriculture
was granted to perform research and experiments on animals
(authorization number 75–369), and the study was approved
by the local ethical committee (Univ Paris-Diderot). Mice were
fed a standard laboratory diet (CRM, Special Diets Services,
Dietex, France Usine). Number of mice and suffering were
minimized as possible. Ts65Dn mice (Davisson et al., 1993)
were maintained on a B6/C3H background and genotyped as
described previously (Reinholdt et al., 2011). Mice carrying the
murine BAC containing one copy of Dyrk1A (mBACtgDyrk1a)
were maintained on a C57BL/6J background and genotyped as
described (Guedj et al., 2012). (See Supplementary Table 1).
EGCG Treatment
For EGCG treatment, a final concentration of 225mg/kg/day
of Polyphenon 60 (POL60, Sigma) in water was delivered via
drinking water to adult (3–4 months) male mice for 4 weeks
for mBACtgDyrk1a, or for 4 weeks before and during behavioral
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TABLE 1 | Protein levels of markers of inhibition and excitation pathways for WT and mBACtgDyrk1a (TG) in cortex, hippocampus, and cerebellum
following treatment with EGCG-containing POL60 extract.
Inhibitors
Comparison
Markers
POL 60 -EGCG 67.5mg/kg POL 60 -EGCG 67.5mg/kg POL 60 -EGCG 67.5mg/kg
TG/WT TG*/WT TG*/TG TG/WT TG*/WT TG*/TG TG/WT TG*/WT TG*/TG
CTX HPC CRB
DYRK1A
162.2 ± 3.3 174.3 ± 5.4 174.3 ± 5.4 199.8 ± 9.2 208.8 ± 17 208.8 ± 17 208.7 ± 18.4 145.2 ± 11.8 145.2 ± 11.8
p < 0.0001 p < 0.0001 p = 0.07 p < 0.0001 p < 0.0001 p = 0.64 p < 0.0001 p = 0.004 p = 0.01
GAD67
131.9 ± 6.6 108.1 ± 7.1 108.1 ± 7.1 142.2 ± 5.4 109.8 ± 8.4 109.8 ± 8.4 155.8 ± 8.9 117.6 ± 10.8 117.6 ± 10.8
p < 0.0006 p = 0.35 p = 0.02 p = 0.01 p = 0.38 p = 0.004 p = 0.003 p = 0.4 p = 0.01
GAD65
136.4 ± 4 112.0 ± 5.1 112.0 ± 5.1 121.4 ± 2 112.7 ± 2.6 112.7 ± 2.6 145.8 ± 9.0 147.3 ± 5.4 147.3 ± 5.4
p = 0.0001 p = 0.07 p = 0.0015 p < 0.0001 p = 0.001 p = 0.01 p = 0.001 p < 0.0001 p = 0.8
VGAT
123.6 ± 2.9 105.3 ± 4 105.3 ± 4 125.3 ± 4.4 99.46 ± 9.2 99.46 ± 9.2 115.5 ± 3.5 106.2 ± 2.6 106.2 ± 2.6
p < 0.0001 p = 0.21 p = 0.002 p = 0.0003 p = 0.9 p = 0.01 p = 0.0004 p = 0.07 p = 0.05
GLUR1
89.70 ± 2.9 105.8 ± 4.9 105.8 ± 4.9 93.71 ± 2.4 93.44 ± 3.5 93.44 ± 3.5 67.25 ± 7.0 66.55 ± 4.09 66.55 ± 4.09
p = 0.01 p = 0.35 p = 0.01 p = 0.1 p = 0.15 p = 0.9 p = 0.001 p < 0.0001 p = 0.9
GLUR2
94.93 ± 2 86.89 ± 2.6 86.89 ± 2.6 83.63 ± 1.9 95.20 ± 2.7 95.20 ± 2.7 63.61 ± 2.4 86.44 ± 3.1 86.44 ± 3.1
p = 0.12 p = 0.001 p = 0.02 p = 0.0001 p = 0.23 p = 0.002 p < 0.0001 p = 0.01 p < 0.0001
NR1
92.60 ± 3 92.16 ± 5.4 92.16 ± 5.4 88.38 ± 2.2 107.8 ± 7.2 107.8 ± 7.2 96.90 ± 3.7 94.35 ± 2.1 94.35 ± 2.1
p = 0.09 p = 0.2 p = 0.9 p = 0.02 p = 0.33 p = 0.01 p = 0.7 p = 0.45 p = 0.55
NR2A
87.47 ± 2.1 101.4 ± 9.3 101.4 ± 9.3 81.10 ± 1.9 100.4 ± 7.0 100.4 ± 7.0 72.12 ± 4.7 63.69 ± 3.4 63.69 ± 3.4
p = 0.001 p = 0.9 p = 0.1 p = 0.001 p = 0.9 p = 0.01 p = 0.002 p = 0.0001 p = 0.17
VGLUT1
84.08 ± 1.8 107.8 ± 4.4 107.8 ± 4.4 106.3 ± 1.9 106.3 ± 2.8 106.3 ± 2.8 81.10 ± 4.5 78.04 ± 4.6 78.04 ± 4.6
p = 0.0001 p = 0.17 p = 0.0001 p = 0.04 p = 0.1 p = 0.9 p = 0.01 p = 0.005 p = 0.6
VGAT/VGLUT1
149.7 ± 4.5 98.33 ± 7.3 98.33 ± 7.3 115.5 ± 4.8 92.84 ± 7.4 92.84 ± 7.4 136.7 ± 9.8 142.7 ± 9.3 142.7 ± 9.3
p < 0.0001 p = 0.75 p = 0.0001 p = 0.02 p = 0.36 p = 0.02 p = 0.008 p = 0.002 p = 0.6
pCAMKII/CAMKII
86.32 ± 2.8 72.58 ± 4.5 72.58 ± 4.5 79.32 ± 3.4 99.12 ± 8.1 99.12 ± 8.1 89.30 ± 5.5 93.70 ± 3.8 93.70 ± 3.8
p = 0.02 p = 0.0005 p = 0.02 p = 0.0004 p = 0.9 p = 0.04 p = 0.08 p = 0.5 p <= 0.1
Protein levels relative to the levels detected in wild-type animals (WT: 100). Mean expression relative to WT level ± standard error of the mean (SEM), P-values for the t-test comparing
transgenic (TG) vs. wild-type (WT) with treated transgenic (TG*). (n = 10 for each genotype and for each treatment) CTX, cortex; HPC, Hippocampus; CRB, cerebellum. (Red indicates
an increase, green a decrease, and blue no variation; changes were labeled for tendency toward significance with p≤ 0.1: pink for tendancy toward increase and pale green for tendancy
toward decrease).
analysis (6 weeks) for Ts65Dn; mice were euthanized at the end
of treatment. Ts65Dn mice were euthanized at 6 months of age
for molecular studies. POL60 contains green tea polyphenols
with 27% EGCG, 42% other catechins (EC, ECG, EGC, and
GC) with no effect on DYRK1A activity, and 8% caffeine; 1%
sucrose was added. The placebo consisted of 1% sucrose in
water. Both supplements were prepared fresh daily and offered
ad libitum; water intake was measured on 5 days, and no
difference was observed between the two groups. Decaffeinated
MGTE (Life Extension) contains 45% EGCG and 53% other
catechins. Solid food pellets containing MGTE were produced
at a dose corresponding to 60mg/kg/day EGCG; placebo was
the ordinary solid diet. Caffeine-containing food pellets were
produced at a dose corresponding to that absorbed from the
POL60 supplement, i.e., 18mg/kg/day. For each experiment, four
groups of animals were used: wild-type (WT) and transgenic
[TG; or trisomic (TS)] with placebo, WT and TG (or TS) with
treatment.
Behavioral Analyses
To assess working memory impairment spontaneous alternation
behavior was recorded in the Y-maze paradigm for the four
groups of male WT and Tg/Ts animals as described in the
Supplemental Methods section.
Tissue Collection
Male mice (3–4 months old for mBACtgDyrk1a were euthanized
by decapitation, and brain tissue was rapidly removed. For
immunoblotting, tissue was cooled on an ice block, dissected in
less than 3min, and snap-frozen in liquid nitrogen.
Immunoblotting
Immunoblotting was performed following standard Western or
slot blot protocols. Antibodies were selected by Western blot
for their suitability to slot blot analyses (Guedj et al., 2012;
Souchet et al., 2014) (Supplementary Table 2). Digitized images
of immunoblots were obtained using a LAS-3000 imaging system
(Fuji Photo Film Co. Ltd.), and densitometry measurements
were collected with an image analyzer (UnScan It software, Silk
Scientific Inc.). Quantification of total proteins after Ponceau-S
coloration was used as an internal control.
Statistical Analysis
For comparisons between groups analyzed by two, TG/WT, TG
treated/WT, TG treated/TG, t-tests were performed. All graphs
were plotted as mean± SEM.
Data were considered significant when p ≤ 0.05: inTables 1–6
a color code was used with red and green for significant increase
and decrease respectively. A p-value of 0.06–0.10 was considered
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TABLE 2 | Protein levels of markers of inhibition and excitation pathways for WT and Ts65Dn (TS) in cortex, hippocampus, and cerebellum following
treatment with POL60 extract.
Inhibitors
Comparison
Markers
POL 60 -EGCG 67.5mg/kg POL 60 -EGCG 67.5mg/kg POL 60 -EGCG 67.5mg/kg
TS/WT TS*/WT TS*/TS TS/WT TS*/WT TS*/TS TS/WT TS*/WT TS*/TS
CTX HPC CRB
DYRK1A
164.3 ± 20.3 128.7 ± 10.9 128.7 ± 10.9 168.0 ± 24.2 136.1 ± 10.9 136.1 ± 10.9 168.0 ± 24.2 136.1 ± 10.9 136.1 ± 10.9
p = 0.01 p = 0.05 p = 0.12 p = 0.02 p = 0.03 p = 0.2 p = 0.02 p = 0.03 p = 0.21
GAD67
144.4 ± 20 84.34 ± 10.4 84.34 ± 10.4 189.3 ± 48.4 109.0 ± 17.4 109.0 ± 17.4 152.2 ± 22.4 147.9 ± 22 147.9 ± 22
p = 0.04 p = 0.35 p = 0.01 p = 0.09 p = 0.73 p = 0.1 p = 0.06 p = 0.1 p = 0.89
GAD65
117.7 ± 7.5 105.1 ± 5.2 105.1 ± 5.2 125.8 ± 14.7 101.8 ± 4.8 101.8 ± 4.8 123.1 ± 10 128.1 ± 10 128.1 ± 10
p = 0.06 p = 0.45 p = 0.21 p = 0.09 p = 0.57 p = 0.1 p = 0.09 p = 0.05 p = 0.7
VGAT
213.3 ± 42.9 87.47 ± 24.6 87.47 ± 24.6 129.1 ± 13.7 104.7 ± 5.8 104.7 ± 5.8 144.3 ± 11.8 121.6 ± 5 121.6 ± 5
p = 0.05 p = 0.74 p = 0.01 p = 0.09 p = 0.68 p = 0.1 p = 0.008 p = 0.03 p = 0.08
GLUR1
84.17 ± 3.2 104.6 ± 6.0 104.6 ± 6.0 105.8 ± 5.7 98.69 ± 6.2 98.69 ± 6.2 86.66 ± 13.5 79.61 ± 8.2 79.61 ± 8.2
p = 0.005 p = 0.53 p = 0.02 p = 0.42 p = 0.8 p = 0.4 p = 0.4 p = 0.12 p = 0.6
GLUR2
77.05 ± 8.04 97.08 ± 6.3 97.08 ± 6.3 106.4 ± 7.9 107.5 ± 6.8 107.5 ± 6.8 98.93 ± 9.5 98.18 ± 6.1 98.18 ± 6.1
p = 0.04 p = 0.74 p = 0.06 p = 0.52 p = 0.43 p = 0.92 p = 0.94 p = 0.8 p = 0.9
NR1
105.2 ± 5.5 100.1 ± 4 100.1 ± 4 85.25 ± 3.6 96.9 ± 4.7 96.9 ± 4.7 85.25 ± 3.6 96.95 ± 4.7 96.95 ± 4.7
p = 0.45 p = 0.94 p = 0.45 p = 0.07 p = 0.7 p = 0.08 p = 0.07 p = 0.7 p = 0.08
NR2A
99.87 ± 3.1 106.9 ± 3.6 106.9 ± 3.6 99.44 ± 8.1 85.09 ± 7.4 85.09 ± 7.4 82.71 ± 3.1 82.48 ± 4.4 82.48 ± 4.4
p = 0.98 p = 0.27 p = 0.17 p = 0.7 p = 0.26 p = 0.21 p = 0.01 p = 0.02 p = 0.9
VGLUT1
88.45 ± 2.18 103.7 ± 3.7 103.7 ± 3.7 91.24 ± 2.4 100.5 ± 3.7 100.5 ± 3.7 106.1 ± 7.4 102.3 ± 5 102.3 ± 5
p = 0.01 p = 0.5 p = 0.008 p = 0.02 p = 0.9 p = 0.08 p = 0.36 p = 0.47 p = 0.6
VGAT/VGLUT1
247.4 ± 55.5 87.86 ± 25.9 87.86 ± 25.9 142.5 ± 16.5 106.7 ± 4.3 106.7 ± 4.3 138.5 ± 12.1 118.9 ± 7.1 118.9 ± 7.1
p = 0.04 p = 0.73 p = 0.01 p = 0.03 p = 0.44 p = 0.04 p = 0.01 p = 0.05 p = 0.18
pCAMKII/CAMKII
50.32 ± 12.6 102.1 ± 17.9 102.1 ± 17.9 59.08 ± 14.1 124.1 ± 20.1 124.1 ± 20.1 75.59 ± 5.3 66.06 ± 3.5 66.06 ± 3.5
p = 0.05 p = 0.9 p = 0.05 p = 0.08 p = 0.36 p = 0.03 p = 0.05 p = 0.03 p = 0.15
Protein levels relative to the levels detected in wild-type animals (WT: 100). Mean expression relative to WT level ± standard error of the mean (SEM), P-values for the t-test comparing
trisomic (TS) vs. wild-type (WT) with treated trisomic (TS*). (n = 10) CTX, cortex; HPC, Hippocampus; CRB, cerebellum. (Red indicates an increase, green a decrease, and blue no
variation; changes were labeled for tendency toward significance with p ≤ 0.1: pink for tendancy toward increase and pale green for tendancy toward decrease).
to indicate a strong statistical tendency due to the small sample
size: in Tables 1–6 tendancy to an increase was coded in pink and
tendancy to a decrease was coded in pale green.
Behavioral analyses were performed using the Mann-Whitney
test as the non-normality of data precluded the use of parametric
statistics (e.g., analysis of variance). All statistical analyses were
performed using GraphPad6 software package.
Results
Effects of POL60 Extract Treatment
mBACtgDyrk1a Mice
To better understand the previously observed effects of EGCG
treatment on improving behavioral outcomes in DS mouse
models, as well as humans with DS, adult WT and TG mice
were treated for 1 month with POL60 diluted in water, with
an average consumption of 3–5mL per day, corresponding to a
dose of 60mg/kg EGCG. Markers involved in both GABAergic
and glutaminergic synaptic plasticity pathways and previously
characterized in various DYRK1A murine models were assessed
by immunoblot to characterize the impact of treatment on
E/I balance (Figure 1, Table 1). In the cortex, hippocampus,
and cerebellum, overexpression of DYRK1A generally promoted
higher protein levels of GABAergicmarkers in Tgmice compared
to WT, but these levels decreased following EGCG treatment.
GAD67 expression was altered in all three brain regions, while
VGAT was affected only in cortex and hippocampus. In contrast,
protein levels of glutaminergic markers GLUR1, NR1, NR2a,
and VGLUT1 were lower in cortex of Tg mice, but their levels
returned to that ofWT following treatment. Similar changes were
observed in the hippocampus, with the exception of VGLUT1,
which was not altered in the hippocampus of transgenic animals.
We observed a weaker correction of GABAergic markers in
the cerebellum than in other brain regions, and no correction
of glutaminergic markers in the cerebellum. The ratio of
PCAMKII/CAMKII, an indicator of LTP status, was lower in TG
mice in all three brain regions analyzed; a rescue effect following
EGCG treatment was observed only in the hippocampus.
Ts65Dn Mice
The same POL60 oral treatment was applied to adult Ts65Dn
animals to assess the effect of treatment in the trisomic
context. After 1 month of treatment, short-term memory was
assessed using spontaneous alternation in the Y maze (Figure 2).
Percentage of alternation was lower in Ts65Dn animals than in
WT (P = 0.0002). However, this difference was rescued by
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TABLE 3 | Protein levels of markers of inhibition and excitation pathways for WT and mBACtgDyrk1a (Tg) in cortex following treatment with 3 doses of
MGTE extract.
Inhibitors
Comparison
Markers
MGTE- EGCG I- 10mg/kg MGTE- EGCG II- 60mg/kg MGTE- EGCGIII- 360mg/kg
TG/WT TG*/WT TG*/TG TG*/WT TG*/TG TG*/WT TG*/TG
Cortex
DYRK1A
162.2 ± 3.3 139.1 ± 7.9 139.1 ± 7.9 148.2 ± 8.0 148.2 ± 8.0 193.4 ± 14.0 193.4 ± 14.0
p < 0.0001 p < 0.0001 p = 0.01 p < 0.0001 p = 0.1 p < 0.0001 p = 0.02
GAD67
131.9 ± 6.6 133.7 ± 10.8 133.7 ± 10.8 131.2 ± 5.7 131.2 ± 5.7 159.5 ± 15.6 159.5 ± 15.6
p = 0.0006 p = 0.0007 p = 0.8 p = 0.0003 p = 0.9 p < 0.0001 p = 0.08
GAD65
136.4 ± 4 114.3 ± 7.0 114.3 ± 7.0 115.2 ± 6.4 115.2 ± 6.4 131.3 ± 8.9 131.3 ± 8.9
p < 0.0001 p = 0.04 p = 0.01 p = 0.05 p = 0.01 p = 0.002 p = 0.56
VGAT
123.6 ± 2.9 99.98 ± 5.3 99.98 ± 5.3 94.53 ± 3.7 94.53 ± 3.7 102.6 ± 3.7 102.6 ± 3.7
p < 0.0001 p = 0.9 p = 0.0009 p = 0.35 p < 0.0001 p = 0.7 p = 0.0004
NR1
92.60 ± 3 99.53 ± 5.3 99.53 ± 5.3 91.98 ± 4.9 91.98 ± 4.9 85.50 ± 3.3 85.50 ± 3.3
p = 0.09 p = 0.87 p = 0.1 p = 0.1 p = 0.9 p = 0.006 p = 0.1
NR2A
87.47 ± 2.1 101.8 ± 4.5 101.8 ± 4.5 98.00 ± 2.6 98.00 ± 2.6 90.54 ± 2.6 90.54 ± 2.6
p = 0.001 p = 0.8 p = 0.007 p = 0.6 p = 0.006 p = 0.01 p = 0.37
GLUR1
89.70 ± 2.9 94.90 ± 4.9 94.90 ± 4.9 106.7 ± 4.5 106.7 ± 4.5 111.3 ± 6 111.3 ± 6
p = 0.01 p = 0.39 p = 0.36 p = 0.25 p = 0.006 p = 0.15 p = 0.005
GLUR2
94.93 ± 2 91.06 ± 2.4 91.06 ± 2.4 98.26 ± 4.2 98.26 ± 4.2 88.80 ± 1.9 88.80 ± 1.9
p = 0.1 p = 0.12 p = 0.24 p = 0.8 p = 0.5 p = 0.008 p = 0.05
VGLUT1
84.08 ± 1.8 96.27 ± 3.6 96.27 ± 3.6 95.16 ± 3 95.16 ± 3 101.2 ± 5.9 101.2 ± 5.9
p = 0.0001 p = 0.34 p = 0.005 p = 0.19 p = 0.005 p = 0.8 p = 0.006
VGAT/VGLUT1
149.7 ± 4.5 118.7 ± 2.1 118.7 ± 2.1 110.0 ± 4.9 110.0 ± 4.9 115.8 ± 7.3 115.8 ± 7.3
p < 0.0001 p = 0.02 p = 0.02 p = 0.22 p = 0.0001 p = 0.08 p = 0.01
pCAMKII/CAMKII
86.32 ± 2.8 80.14 ± 11.7 80.14 ± 11.7 52.77 ± 5.3 52.77 ± 5.3 102.1 ± 11.8 102.1 ± 11.8
p = 0.01 p = 0.08 p = 0.48 p < 0.0001 p < 0.0001 p = 0.79 p = 0.08
Protein levels relative to the levels detected in wild-type animals (WT: 100). Mean expression relative to WT level ± standard error of the mean (SEM), P-values for the t-test comparing
transgenic (TG) vs. wild-type (WT) with treated transgenic (TG*). (n= 10). (Red indicates an increase, green a decrease, and blue no variation; changes were labeled for tendency toward
significance with p ≤ 0.1: pink for tendancy toward increase and pale green for tendancy toward decrease).
POL60, with a significant increase of spontaneous alternation
after treatment (p = 0.0022).
After these behavioral assessments, mice were euthanized and
brains were collected and analyzed as for mBACtgDyrk1a mice.
As was observed in the TGmice, the levels of GABAergic markers
were higher in all three brain regions, and levels of glutaminergic
markers were lower (with the exception of GLUR1 and GLUR2 in
hippocampus) in TS mice compared to WT (Table 2). However,
treatment with POL60 resulted in rescued levels of GABAergic
and glutaminergic markers in cortex and hippocampus. Further,
the ratio of pCAMKII/CAMKII, which was significantly lower in
Ts65Dn mice, was rescued by treatment. In contrast, treatment
did not modify the alterations observed in the cerebellum
(Table 2).
Treatment with MGTE in mBACtgDyrk1a Mice:
Dose Effects and Behavioral Rescue
For translational purposes, we chose to continue our analyses
with an extract used for food supplementation or direct
consumption in humans: MGTE, which contains 45% EGCG
and three other catechins. To select the right dose of EGCG,
the effects of three doses were compared: a dose 6 times lower
than the EGCG doses previously used (dose I = 10mg/kg); a
dose similar to the previous experiments (dose II = 60mg/kg);
and a dose 6 times higher than the intermediate dose (dose
III = 360mg/kg). WT and Tg adult (3–4 months) mice were
treated with MGTE-supplemented solid food with an average
consumption of 3–5 g per day. The same GABAergic and
glutaminergic markers in cortex, hippocampus, and cerebellum
were assessed following euthanization. To determine the true
defect due to transgenesis, we used the average values of
expression levels obtained for 10 WT/10 TG (3–5 experiments
for each marker), and these values were compared to the values
obtained for treated animals (n = 10 for WT and TG). In cortex
(Table 3) we observed a tendency toward lower DYRK1A and
GAD65 following treatment with low and intermediate doses.
GAD67 levels were not modified by the low and intermediate
doses, but were significantly higher after high-dose treatment.
DYRK1A was significantly lower following high-dose treatment.
VGAT and VGLUT1 levels were rescued by all three doses. NR1
and NR2A levels were rescued by low-dose treatment, and NR2A
also by the intermediate dose. PCAMKII/CAMKII was rescued
only by dose III. Thus, in cortex the intermediate dose (dose
II) appeared to be the best compromise to rescue normal levels
of VGAT/VGLUT1 and to avoid the increase in GAD67 and
DYRK1A levels observed with dose III.
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TABLE 4 | Protein levels of markers of inhibition and excitation pathways for WT and mBACtgDyrk1a (TG) in hippocampus following treatment with 3
doses of MGTE extract.
Inhibitors
Comparison
Markers
MGTE-EGCG I- 10mg/kg MGTE-EGCG II- 60mg/kg MGTE-EGCGIII- 360 mg/kg
TG/WT TG*/WT TG*/TG TG*/WT TG*/TG TG*/WT TG*/TG
Hippocampus
DYRK1A
199.8 ± 9.2 164.9 ± 4.2 164.9 ± 4.2 129.5 ± 5.2 129.5 ± 5.2 164.4 ± 3.7 164.4 ± 3.7
p < 0.0001 p < 0.0001 p = 0.004 p = 0.002 p = 0.0001 p < 0.0001 p = 0.008
GAD67
142.2 ± 5.4 123.5 ± 8.3 123.5 ± 8.3 123.8 ± 5.1 123.8 ± 5.1 148.4 ± 8.6 148.4 ± 8.6
p < 0.0001 p = 0.01 p = 0.07 p = 0.001 p = 0.02 p < 0.0001 p = 0.46
GAD65
121.4 ± 2 122.1 ± 5.4 122.1 ± 5.4 118.2 ± 4.8 118.2 ± 4.8 117.1 ± 4.4 117.1 ± 4.4
p < 0.0001 p < 0.0001 p = 0.8 p = 0.002 p = 0.7 p = 0.0006 p = 0.7
VGAT
125.3 ± 4.4 95.55 ± 7.2 95.55 ± 7.2 102.9 ± 5.3 102.9 ± 5.3 101.2 ± 5.4 101.2 ± 5.4
p = 0.0003 p = 0.47 p = 0.002 p = 0.57 p = 0.005 p = 0.8 p = 0.003
GLUR1
93.71 ± 2.4 83.72 ± 2.4 83.72 ± 2.4 94.06 ± 6.0 94.06 ± 6.0 92.94 ± 2.5 92.94 ± 2.5
p = 0.1 p = 0.003 p = 0.01 p = 0.31 p = 0.9 p = 0.24 p = 0.43
GLUR2
83.63 ± 1.9 90.28 ± 2.6 90.28 ± 2.6 99.42 ± 1.9 99.42 ± 1.9 90.49 ± 4.8 90.49 ± 4.8
p = 0.0001 p = 0.1 p = 0.05 p = 0.9 p = 0.0001 p = 0.15 p = 0.26
NR1
88.38 ± 2.2 108.3 ± 6.9 108.3 ± 6.9 113.2 ± 7.1 113.2 ± 7.1 133.9 ± 7.2 133.9 ± 7.2
p = 0.02 p = 0.31 p = 0.01 p = 0.1 p = 0.005 p = 0.0005 p < 0.0001
NR2A
81.10 ± 1.9 82.25 ± 4.4 82.25 ± 4.4 121.8 ± 6.7 121.8 ± 6.7 110.8 ± 4.6 110.8 ± 4.6
p = 0.001 p = 0.01 p = 0.78 p = 0.02 p < 0.0001 p = 0.29 p < 0.0001
VGLUT1
106.4 ± 3.1 98.46 ± 5.7 98.46 ± 5.7 93.32 ± 4.3 93.32 ± 4.3 98.60 ± 5.0 98.60 ± 5.0
p = 0.05 p = 0.61 p = 0.23 p = 0.05 p = 0.02 p = 0.7 p = 0.24
VGAT/VGLUT1
115.5 ± 4.8 89.13 ± 4.8 89.13 ± 4.8 111.2 ± 3.9 111.2 ± 3.9 103.8 ± 5.8 103.8 ± 5.8
p = 0.02 p = 0.07 p = 0.001 p = 0.05 p = 0.5 p = 0.58 p = 0.1
pCAMKII/CAMKII
79.33 ± 3.3 75.63 ± 6.6 75.63 ± 6.6 99.77 ± 12.3 99.77 ± 12.3 96.93 ± 7.4 96.93 ± 7.4
p = 0.0004 p = 0.005 p = 0.59 p = 0.89 p = 0.1 p = 0.81 p = 0.04
Protein levels relative to the levels detected in wild-type animals (WT: 100). Mean expression relative to WT level ± standard error of the mean (SEM), P-values for the t-test comparing
transgenic (TG) vs. wild-type (WT) with treated transgenic (TG*). (n= 10). (Red indicates an increase, green a decrease, and blue no variation; changes were labeled for tendency toward
significance with p ≤ 0.1: pink for tendancy toward increase and pale green for tendancy toward decrease).
In hippocampus (Table 4), where the basal level of
overexpression of DYRK1A was high, we observed lower,
but not normal, DYRK1A levels after treatment of TG mice with
the three doses. Neither GAD67 nor GAD65 were modified by
the treatment. However, VGAT was rescued to a normal level
at all three EGCG doses. Notably, the levels of three markers
of the glutaminergic pathway, GLUR2, NR1, and NR2A, were
corrected when using treatment II. For NR2A, this correction
significantly exceeded the normal level.
In cerebellum (Table 5), the treatments induced significant
decreases in levels of DYRK1A at doses I and II, and increases
in GAD67 at doses II and III. VGAT1 was not modified by the
treatment. The only rescuing effect was observed for GLUR1 and
GLUR2, at doses II and III. The ratio of VGAT/VGLUT1, which
is higher in untreated transgenic mice, was significantly increased
by the three MGTE doses.
We used a spontaneous alternation paradigm (similar to
the Y–maze experiment performed with POL60 treated Ts65Dn
mice) to assess the effects of DYRK1A overexpression on short-
term spatial working memory. We found that the exploratory
activity in the Y-maze was affected by Dyrk1a overexpression:
the total number of arm entries was higher in mBACtgDyrk1a
mice compared with wild type animals in both conditions of
treatment (placebo and MGTE, p = 0.012 and p = 0.009
respectively).
The rate of spontaneous alternation (visiting each arm in
turn) was affected by genotype: mBACtgDyrk1a mice alternated
less than wild-type mice (p = 0.017, Figure 3). Noteworthy,
treatment improved the rate of spontaneous alternation of
mBACtgDryk1a mice (p = 0.03).
Treatment with Caffeine in mBACtgDyrk1a Mice:
Molecular Effects
To explain the differences observed in the corrections of
GAD67 levels between POL60 treatment and MGTE treatment,
we hypothesized an effect of the caffeine contained in green
tea and present in POL60 extract. We designed a caffeine-
supplemented solid diet alone with a caffeine dose (18mg/kg)
equivalent to the dose given to mice treated with POL60. After
1 month of treatment, adult mBACtgDyrk1a and wild-type mice
animals were euthanized and brains collected and analyzed
(Table 6). In cortex, we observed significantly decreased levels of
markers of GABAergic neurotransmission: levels of GAD67 and
VGAT1 and the ratio of VGAT/VGLUT1 were partially rescued.
In hippocampus, rescue of these markers was complete. In
contrast, in cortex and hippocampus, markers of glutaminergic
neurotransmission, GLUR1 and GLUR2, remained at low levels
after treatment, and the levels of NR1 and NR2A were further
decreased after treatment.
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TABLE 5 | Protein levels of markers of inhibition and excitation pathways for WT and mBACtgDyrk1a (Tg) in cerebellum following treatment with 3 doses
of MGTE extract.
Treatment
Markers
MGTE-EGCG I- 10mg/kg MGTE-EGCG II- 60mg/kg MGTE-EGCGIII- 360mg/kg
TG/WT TG*/WT TG*/TG TG*/WT TG*/TG TG*/WT TG*/TG
Cerebellum
DYRK1A
171.0 ± 9 136.5 ± 9.7 136.5 ± 9.7 139.4 ± 7.0 139.4 ± 7.0 155.6 ± 13.9 155.6 ± 13.9
p < 0.0001 p = 0.003 p = 0.01 p = 0.0002 p = 0.01 p < 0.0001 p = 0.35
GAD67
159.8 ± 6.7 150.6 ± 13.0 150.6 ± 13.0 181.4 ± 10.9 181.4 ± 10.9 188.6 ± 17.3 188.6 ± 17.3
p = 0.0001 p = 0.002 p = 0.5 p = 0.0001 p = 0.1 p < 0.0001 p = 0.1
GAD65
139.6 ± 5.1 138.1 ± 5.6 138.1 ± 5.6 148.2 ± 9.05 148.2 ± 9.05 168.2 ± 13.6 168.2 ± 13.6
p = 0.0001 p < 0.0001 p = 0.85 p = 0.0002 p = 0.41 p = 0.0001 p = 0.04
VGAT
122.6 ± 3.2 136.6 ± 4.0 136.6 ± 4.0 133.6 ± 3.6 133.6 ± 3.6 135.3 ± 3.9 135.3 ± 3.9
p < 0.0001 p < 0.0001 p = 0.68 p < 0.0001 p = 0.04 p < 0.0001 p = 0.02
GLUR1
82.87 ± 2.6 98.01 ± 5.3 98.01 ± 5.3 92.62 ± 5.3 92.62 ± 5.3 100.7 ± 6.2 100.7 ± 6.2
p = 0.0005 p = 0.74 p = 0.01 p = 0.21 p = 0.1 p = 0.91 p = 0.01
GLUR2
87.94 ± 2.7 103.6 ± 3.6 103.6 ± 3.6 107.2 ± 2.8 107.2 ± 2.8 111.7 ± 4.7 111.7 ± 4.7
p = 0.009 p = 0.48 p = 0.003 p = 0.09 p = 0.0001 p = 0.04 p = 0.0005
NR1
98.84 ± 1.6 90.71 ± 2.6 90.71 ± 2.6 94.11 ± 4.1 94.11 ± 4.1 94.18 ± 3.5 94.18 ± 3.5
p = 0.7 p = 0.08 p = 0.01 p = 0.3 p = 0.28 p = 0.2
NR2A
85.2 ± 2.9 94.08 ± 5.6 94.08 ± 5.6 89.99 ± 3.6 89.99 ± 3.6 91.1 ± 3.8 91.15 ± 3.8
p = 0.001 p = 0.4 p = 0.15 p = 0.04 p = 0.36 p = 0.07 p = 0.31
VGLUT1
84.5 ± 2 83.82 ± 2.7 83.82 ± 2.7 81.72 ± 3.0 81.72 ± 3.0 77.67 ± 2.1 77.67 ± 2.1
p < 0.0001 p = 0.0005 p = 0.66 p = 0.0001 p < 0.33 p < 0.0001 p = 0.07
VGAT/VGLUT1
141.6 ± 5.1 161.1 ± 3.7 161.1 ± 3.7 162.0 ± 8.4 162.0 ± 8.4 173.1 ± 7.8 173.1 ± 7.8
p < 0.0001 p < 0.0001 p = 0.008 p < 0.0001 p = 0.06 p < 0.0001 p = 0.004
Protein levels relative to the levels detected in wild-type animals (WT: 100). Mean expression relative to WT level ± standard error of the mean (SEM), P-values for the t-test comparing
transgenic (TG) vs. wild-type (WT) with treated transgenic (TG*). (n= 10). (Red indicates an increase, green a decrease, and blue no variation; changes were labeled for tendency toward
significance with p ≤ 0.1: pink for tendancy toward increase and pale green for tendancy toward decrease).
Discussion
We found that DYRK1A protein level is associated with
expression levels of proteins involved in synaptic plasticity.
Specifically, enzymes involved in decarboxylation of glutamate
to produce GABA and in vesicular transport of GABA are
found at higher levels in mice with three copies of Dyrk1a.
In Dyrk1a single-copy mice, only GABA-producing enzymes
are detected at lower levels than in WT (Souchet et al.,
2014); the increase in VGAT1 in hippocampus and cortex
may be compensating for these reductions. In contrast, in the
cerebellum GAD67 and VGAT levels were changed in the
same direction. Thus, molecular data suggest that increasing
Dyrk1a dosage induces activation of the GABA pathway with
an increased production and transport of GABA; decreasing
the level of Dyrk1a induces a decrease in both GADs. These
molecular changes offer mechanistic support for behavioral
phenotypes observed in mouse models. In Ts65Dn, excessive
GABAergic neurotransmission results in local over-inhibition
of hippocampal circuits, which dampens hippocampal synaptic
plasticity and contributes to cognitive impairments; treatment
with several GABA-A receptor antagonists results in increased
plasticity and improved memory deficits in Ts65Dn mice
(Fernandez et al., 2007). Deficits in cognition and synaptic
plasticity in Ts65Dn are also ameliorated by a selective inverse
agonist of GABA-A receptor α5 subtype (Braudeau et al., 2011)
or by GABA-B receptor antagonists (Kleschevnikov et al., 2012).
Reducing GABA-A α5 receptor-mediated inhibition normalizes
the high density of GABAergic synapse markers in the molecular
layer of the hippocampus of TS mice (Martinez-Cue et al.,
2013).
Here we report the phenotypic rescues observed in adult
murine models of DS after a 1-month oral treatment with green
tea extracts containing EGCG. We propose a molecular clue to
understand the mechanisms of increased inhibition in DS and for
the correcting effects of EGCG.
EGCG-containing Extracts Rescue Components
of E/I Balance
For the first time, we compared the effect of an inhibitor
of DYRK1A, EGCG, on the molecular phenotypes of adult
mBACtgDyrk1a mice and Ts65Dn mice. We previously
showed the gene dosage effect of Dyrk1a on GABAergic and
glutaminergic pathways in models with increased DYRK1A
expression and decreased DYRK1A expression. DYRK1A dose
has an impact on the levels of GABA-synthesizing enzymes
GAD67 and GAD65, but also on GABA transporter VGAT.
DYRK1A dose also affects excitatory processes and modifies
levels of glutamate receptors GLUR1 and GLUR2, of a glutamate
transporter VGLUT1, and components of the NMDA receptor,
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TABLE 6 | Protein levels of markers of inhibition and excitation pathways for WT and mBACtgDyrk1a (Tg) in cortex and hippocampus following treatment
with caffeine.
Inhibitors
Comparison
Markers
Caffeine Caffeine
TG/WT TG*/WT TG*/TG TG/WT TG*/WT TG*/TG
CTX HPC
DYRK1A
162.2 ± 3.3 180.1 ± 8.1 180.1 ± 8.1 199.8 ± 9.2 149.4 ± 14 149.4 ± 14
p < 0.0003 p < 0.0001 p = 0.8 p < 0.0001 p < 0.0001 p = 0.006
GAD67
131.9 ± 6.6 110.3 ± 7.8 110.3 ± 7 142.2 ± 5.4 103.7 ± 9.2 103.7 ± 9.2
p = 0.0006 p = 0.22 p = 0.05 p < 0.0001 p = 0.8 p = 0.001
VGAT
123.6 ± 2.9 109.3 ± 7.9 109.3 ± 7.9 125.3 ± 4.4 99.46 ± 9.2 99.46 ± 9.2
p < 0.0001 p = 0.2 p = 0.07 p = 0.0003 p = 0.9 p = 0.008
GLUR1
89.70 ± 2.9 85.94 ± 2.8 85.94 ± 2.8 93.71 ± 2.4 93.44 ± 3.5 93.44 ± 3.5
p = 0.01 p = 0.002 p = 0.39 p = 0.1 p = 0.1 p = 0.9
GLUR2
94.93 ± 2 96.86 ± 5 96.86 ± 5 83.63 ± 1.9 85.94 ± 2.8 85.94 ± 2.8
p = 0.1 p = 0.58 p = 0.9 p = 0.0001 p = 0.003 p = 0.5
NR1
92.60 ± 3 85.18 ± 3.8 85.18 ± 3.8 88.38 ± 2.2 68.20 ± 5.6 68.20 ± 5.6
p = 0.09 p = 0.01 p = 0.1 p = 0.02 p = 0.0004 p = 0.001
NR2A
87.47 ± 2.1 69.23 ± 4 69.23 ± 4 81.10 ± 1.9 76.56 ± 7.3 76.56 ± 7.3
p = 0.001 p < 0.0001 p = 0.0005 p = 0.001 p = 0.01 p = 0.49
VGLUT1
84.08 ± 1.8 91.54 ± 2.7 91.54 ± 2.7 106.3 ± 1.9 98.12 ± 4.4 98.12 ± 4.4
p < 0.0001 p = 0.01 p = 0.03 p = 0.04 p = 0.5 p = 0.15
VGAT/VGLUT1
149.7 ± 4.5 125.8 ± 9.2 125.8 ± 9.2 115.5 ± 4.8 96.09 ± 7 96.09 ± 7
p < 0.0001 p = 0.01 p = 0.02 p = 0.02 p = 0.56 p = 0.03
pCAMKII/CAMKII
86.35 ± 3.3 100.7 ± 8.6 100.7 ± 8.6 79.32 ± 3.4 115.9 ± 5.5 115.9 ± 5.5
p = 0.02 p = 0.9 p = 0.1 p = 0.0004 p = 0.01 p < 0.0001
Protein levels relative to the levels detected in wild-type animals (WT: 100). Mean expression relative to WT level ± standard error of the mean (SEM), P-values for the t-test comparing
transgenic (TG) vs. wild-type (WT) with treated transgenic (TG*). (n = 10) CTX, cortex; HPC, Hippocampus; CRB, cerebellum. (Red indicates an increase, green a decrease, and blue
no variation; changes were labeled for tendency toward significance with p ≤ 0.1: pink for tendancy toward increase and pale green for tendancy toward decrease).
NR1 and NR2A. Further, overexpression of DYRK1A reduces
the activation of CAMKII, which is accompanied by anomalous
NMDAR-mediated long-term potentiation (Thomazeau et al.,
2014). Treatment with POL60 (27% EGCG) and MGTE
(45% EGCG), given at EGCG equivalent doses (60mg/kg)
produced corrections in the levels of most of these markers,
conducive to a rescue of E/I balance in agreement with
the rescue of working memory. Even if we observed some
differences in molecular alterations between mBACtgDyrk1a
and Ts65Dn mice, which might be linked to the additional gene
context in Ts65Dn, alterations were in the same direction and
were corrected by POL60 treatment in similar ways in both
models.
Molecular Effects are Brain-region Dependent
Most of the E/I markers varied in the same direction between
WT and transgenic or WT and trisomic mice when different
brain regions were compared. However, in mBACtgDyrk1a
VGLUT1 was decreased in cortex and cerebellum but slightly
increased in hippocampus; in Ts65Dn, the same marker was
decreased in cortex and hippocampus and showed a non-
significant increase in cerebellum. POL60 treatment corrected
these alterations in both models, with the exception of GLUR2
and pCAMKII/CAMKII in cortex and in hippocampus of
mBACtgDyrk1a. In cerebellum, in mBACtgDyrk1a we observed
only partial correction for GAD67 and VGAT, and in Ts65Dn
we observed only a partial correction for VGAT. This difference
for cerebellum is intriguing and might be due to a reduced
accessibility of the drug although this hypothesis is not
compatible with the effect of MGTE on DYRK1A or GLUR1-
GLUR2 levels; therefore these differences are most probably
due to the presence of different regulatory mechanisms in
cerebellum.
EGCG Molecular Effects are Dose-dependent
To further analyze molecular effects of EGCG treatment we
compared three doses of decaffeinatedMGTE compound already
used in previous mouse studies and in a pilot trial; the
intermediate EGCG dose was similar to the dose used for the
POL60 study. In cortex the effect of the lower and intermediate
doses on DYRK1A and markers from the GABA system were
similar, with a partial decrease for DYRK1A and GAD65
and a complete correction for VGAT. At the highest dose,
opposite effects were observed for DYRK1A, accompanied by
increased GAD67, potentially exacerbating E/I imbalance. In
hippocampus, low and intermediate doses induced a partial
rescue of DYRK1A and GAD67. Interestingly, the stability of
DYRK1A has been associated with autophosphorylation (Himpel
et al., 2001), an activity that might be decreased in the presence
of inhibitors. In cerebellum, the intermediate and high doses
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FIGURE 1 | Effect of long-term POL60 treatment on GAD67 and NR2A levels in hippocampus: Immunoblotting of proteins from wt and mBACtgDyrk1a
hippocampus treated with placebo or POL60 for (A) GAD67 and (B) NR2A. Ponceau-S coloration was used to assess total protein levels. Below: boxplots of
expression relative to WT placebo (WT) for (C) GAD67 and (D) NR2A. *p < 0.05, **p < 0.01, ****p < 0.0001.
FIGURE 2 | Effect of long-term POL60 treatment on working memory in
Ts65Dn mice: Per cent of alternation was assessed in four groups of mice:
WT and Ts administered placebo, n = 12; and WT and Ts with POL60
treatment, n = 8. The data have been normalized to the baseline level of
performance of wild-type mice fed with water (dotted line). Ts65Dn mice
displayed a very significant decrease of alternation under placebo condition.
POL60 treatment produced improved alternation performance in the Ts65Dn
mice. ***p < 0.001, **p < 0.01.
induced increased GAD67 and ratio of VGAT1/VGLUT1. For the
glutaminergic pathway in cortex, corrections NR1, NR2A, and
VGLUT1 were already present for the lower dose. These findings
suggest that a dose below or close to the intermediate dose is the
best choice for further studies.
EGCG Molecular Effects are Extract-dependent
and Differences are Explained by the Presence of
Caffeine in POL60 Extracts
We observed, particularly in cortex, that a low or intermediate
dose of MGTE does not change the level of GAD67, despite
the rescue of GAD67 levels following treatment with POL60 at
an equivalent dose of EGCG. Comparison of composition of
POL60 and decaffeinated MGTE extracts indicates that POL60
contains a dose corresponding to an 18mg/kg caffeine diet.
Therefore, hypothesizing that caffeine partially mediates the
effects of POL60, we fed mBACtgDyrk1a adult mice an 18mg/kg
caffeine diet in solid food. Brain synaptic marker analysis
revealed that this dose of caffeine was sufficient to induce a partial
rescue of GAD67 and VGAT levels in cortex, and a complete
rescue of these markers in hippocampus. Glutaminergic markers
were not rescued by this treatment. The mode of action of
caffeine is unknown, but might involve an effect on GAD67
via A2A receptors (Carta et al., 2002). Caffeine has no effect
on glutaminergic markers; however, it rescues alterations of
pCAMKII/CAMKII ratio in cortex and induces an increase in
hippocampus in comparison with WT.
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FIGURE 3 | Cognitive performance of GTE (or MGTE)-treated
mBACtgDyrk1a in the Y maze. The effects of Dyrk1A overexpression on
short-term spatial memory were assessed in a spontaneous alternation
paradigm in a Y–maze. The data have been normalized to the baseline level of
performance of wild-type mice fed with water (dotted line). One mouse from
the BACtgDyrk1a group was excluded from statistical analysis because of
abnormally high levels of locomotor activity and associated erratic exploration,
precluding assessment of memory scores. The rate of spontaneous alternation
(visiting each arm in turn) was affected by genotype: mBACtgDyrk1a mice
alternated less than wild-type mice (P < 0.05). Treatment with MGTE
significantly improved performance of mBACtgDyrk1a mice. *p < 0.05.
EGCG-containing Extracts Rescue Short-term
Memory in Transgenic and Trisomic Models
We previously reported that EGCG treatment can rescue spatial
learning (De la Torre et al., 2014) and object recognition
memory (Guedj et al., 2009; De la Torre et al., 2014) deficits
in Ts65Dn mice. Here, we concentrated on short-term memory
impairment. In this case the cortical regions are essential to
the temporary storage and the recall of information over short
time periods, a general process known as working memory.
Lesion experiments have shown that the prelimbic area is
critically involved in working memory (Granon et al., 1994).
Working memory is impaired in DS (Lanfranchi et al., 2014).
Ts65Dn and Ts1Rhr models of DS with partial trisomy of
Mmu16 that includes the Dyrk1a gene (Belichenko et al., 2009;
Faizi et al., 2011) have impaired short-term memory in the
spontaneous alternation paradigm. Normalization of the Dyrk1a
copy number in TS65Dn mice improves working memory
(Garcia-Cerro et al., 2014), indicating that overexpression of
DYRK1A is involved in working memory alterations. In a single-
gene model like the mBACtgDyrk1a mouse, our results are
consistent with the idea that mice overexpressing DYRK1A have
an impaired working memory. Use of EGCG treatment either
in POL60 or in decaffeinated MGTE rescued working memory
in a Y-maze paradigm. MGTE treatment was assessed in a pilot
human clinical trial and reversed the working memory deficit in
individuals with DS (De la Torre et al., 2014). Our results on the
levels of synaptic markers suggest that this rescue is linked with
the effect of EGCG on E/I balance. However, molecular analyses
indicate that POL60 treatment induces a stronger correction of
the level of proteins involved in the GABAergic pathway than
decaffeinated MGTE, an effect that appears to be mediated, in
part, by the presence of caffeine in POL60. We have recently
shown that inhibition of DYRK1A is acting on GABA-producing
enzymes at two different levels, by controlling levels of GAD67
or GAD65 proteins, but also by controlling the activity of these
enzymes: the level of pyridoxal phosphate, a coenzyme of GAD67
and GAD65, is under the control of DYRK1A (Tlili et al., 2013):
therefore an EGCG treatment can modify the activity of GADs
enzymes by inhibiting DYRK1A activity.
Conclusion
Results show that EGCG treatment of adult mice reverses brain
molecular alterations that disrupt E/I balance. Two different
extracts are also efficient to restore working memory in a single-
gene model and in a partial trisomy model of DS. DYRK1A
is thus a therapeutic target for Down syndrome. The panel of
proteins involved in the control of synaptic plasticity and E/I
balance is potentially useful to assess consequences of other
therapeutic strategies, and its use may help to understand
molecular mechanisms involved in these strategies. The partial
rescue of components of the GABAergic pathway observed when
treating adult mice with a decaffeinated green tea extract suggest
the possibility of combining two drugs such as EGCG and an
inverse GABA agonist (Braudeau et al., 2011) to reach a complete
rescue of GABAergic and glutamatergic pathways.
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